Statement by Ralph G. Neas, President and CEO, Generic Pharmaceutical Association, on FDA's Acceptance of Sandoz Biologics License Application for Filgrastim Under the New Biosimilar Pathway

JULY 24, 2014
PRESS RELEASE

“For the first time, the FDA has accepted a filing for an approval of a biosimilar drug, a major step toward access for Americans to safe, effective alternatives to costly brand biologic medicines.

Biosimilars have been successfully used in Europe and other markets for years. Filgrastim’s filing acceptance moves us closer to the day when U.S. patients that currently must rely on costly brand biologics for treatment will have more choices for the medicine that they need.

This approval represents a new frontier — not only for patients, but for our nation’s health system. Express Scripts projects that the United States would save $250 billion between 2014 and 2024 if filgrastim and 10 other biosimilars would enter the market.

We look forward to the integration of biosimilar therapies into the American health system, and witnessing the realization of the transformative potential of these innovative therapies.”


SHARE THIS SHARE THIS
0

Become A RESPIMAT T.O.P. Performer 

Get to know RESPIMAT, the slow-moving mist inhaler from Boehringer Ingelheim Pharmaceuticals, Inc.

Watch the RESPIMAT video and test your knowledge with a short multiple-choice quiz. When you get all the answers right, you’ll receive a certificate naming you a RESPIMAT T.O.P. Performer. Why not check it out today?


Pharmacy Times Strategic Alliance
 

Pharmacist Education
Clinical features with downloadable PDFs


Next-Generation Pharmacist® Awards


3rd Annual Convenient Healthcare and Pharmacy Collaborative Conference


SIGN UP FOR THE PHARMACY TIMES NEWSLETTER
Personalize the information you receive by selecting targeted content and special offers.